Lisata Therapeutics (NASDAQ:LSTA) reported quarterly losses of $(7.88) per share. This is a 352.87 percent decrease over losses of $(1.74) per share from the same period last year.
Ozempic Shortage Crisis – Germany Weighs Export Restrictions on Novo Nordisk’s Drug
Germany's Federal Institute for Drugs and Medical Devices (BfArM) is reportedly contemplating a potential export prohibition on Novo Nordisk A/S's (NYSE: NVO) popular diabetes medication, Ozempic,